Tumour heterogeneity at the protein level has been associated with poor prognosis in several human carcinomas. Current approaches for assessing protein function rely on intensity-based methods, which are limited by their subjectivity and specificity.

We open the Spring Newsletter highlighting the strategies we have adopted to implement creative approaches to secure a larger portion of funding pools with this time focusing on Industrial partnerships.

As a novel alternative to established surface display or combinatorial chemistry approaches for the discovery of therapeutic peptides, we present a method for the isolation of small, cysteine-rich domains from bovine antibody ultralong complementarity-determining regions (CDRs).

It is possible to modify the properties of semicrystalline polymers using diffusion to introduce additional functionality.

Three projects chosen by MATWIN’s 13 partner laboratories, three by a panel of European investors

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

Many cancers are termed immunoevasive due to expression of immunomodulatory ligands. Programmed death ligand-1 (PD-L1) and cluster of differentiation 80/86 (CD80/86) interact with their receptors, programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) respectively, on tumor-infiltrating leukocytes eliciting immunosuppression.

CTI publications span a wide range of research areas. The figure below uses Scopus/SciVal’s broad subject categories to show the areas current CTI staff have published in since 2014.